Cargando…
Conbercept for Treatment of Neovascular Age-Related Macular Degeneration and Visual Impairment due to Diabetic Macular Edema or Pathologic Myopia Choroidal Neovascularization: A Systematic Review and Meta-Analysis
Background: Conbercept is a new anti-vascular endothelial growth factor (VEGF) drug. Here, we systematically conducted the efficacy, safety, compliance, and pharmacoeconomic evaluation of intravitreal conbercept (IVC) compared with other treatments in patients with neovascular age-related macular de...
Autores principales: | Zhou, Pengxiang, Zheng, Siqian, Wang, Ente, Men, Peng, Zhai, Suodi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8546330/ https://www.ncbi.nlm.nih.gov/pubmed/34712132 http://dx.doi.org/10.3389/fphar.2021.696201 |
Ejemplares similares
-
Metabolomics study of treatment response to conbercept of patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy
por: Shen, Yinchen, et al.
Publicado: (2022) -
Efficacy of Conbercept in the Treatment of Choroidal Neovascularization Secondary to Pathologic Myopia
por: Lu, Hui, et al.
Publicado: (2021) -
Profile of conbercept in the treatment of neovascular age-related macular degeneration
por: Lu, Xinmin, et al.
Publicado: (2015) -
Full-Thickness Macular Hole Due to Choroidal Neovascularization in
the Setting of Pathologic Myopia
por: Pereira, Austin, et al.
Publicado: (2022) -
Assessment of conbercept therapy for high myopia macular neovascularization by optical coherence tomography angiography
por: Cheng, Lu-Na, et al.
Publicado: (2020)